Revolo Biotherapeutics Announces Presentations at Upcoming Medical Meetings

Presenting new data on ‘1104 in allergic disease at the American Thoracic Society International Conference in San Francisco on May 17

Delivering an oral presentation on resetting the immune system to achieve long-term disease remission at the Treg Summit in Boston on May 19

NEW ORLEANS, LA and LONDON, UK, May 16, 2022 – Revolo Biotherapeutics (“Revolo Bio” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced that the Company will be delivering presentations at two upcoming medical meetings: the American Thoracic Society (ATS) International Conference and the Treg Summit.

“We are pleased to have a presence at these two important medical conferences,” said Jonathan Rigby, Group Chief Executive Officer of Revolo Biotherapeutics. “The new data presented at ATS 2022 further show the potential of ‘1104 to be used in the clinical setting both through subcutaneous (SC) or intravenous (IV) administration for the treatment of asthma and other allergic and inflammatory diseases. ‘1104 is currently in two phase 2 clinical trials, one in allergic disease and another in eosinophilic esophagitis (EoE), and expansion of routes of administration such as SC allow for wider exploration into other allergic and inflammatory diseases.”

“We are also excited to participate at this year’s Treg Summit and provide a review of new mechanisms directed at proliferating stable and long lasting Tregs to reset the immune system and achieve superior long term disease remission. We will also offer an update on both of our clinical programs for our two drug candidates, ‘1104 and ‘1805. Both drugs increase the number of Tregs via a unique mechanism of action to restore immune system balance, avoiding chronic inflammation without suppressing the immune system and potentially providing much needed therapies for patients suffering from autoimmune and allergic diseases,” Mr. Rigby concluded.

Details of the presentations are as follows:

ATS 2022 Poster Presentation details – May 13-18, San Francisco

Format: Poster
Title: IRL201104, a Novel Immunomodulatory Peptide, Shows a Long Lasting, Dose Response and Wide Spectrum Effect Through Different Routes of Administration in a Model of Allergic Inflammation
Poster Number: 504
Session: C21- Drilling down on inflammatory mechanisms in asthma via human cells and murine models
Poster Discussion Time: May 17, 2022, 9:30-11:30 am EDT (viewing: 9:30-10:00 am EDT; discussion: 10:00-11:30 am EDT)
Room: 303-304 (South Building, Level 3), Moscone Center
Presentation Highlights:

  • Treatment with ‘1104 resulted in a long-lasting dose response through both IV and SC administration in a murine model of allergic disease.
  • ‘1104 led to a reduced inflammatory response at clinically relevant doses as seen by a reduction of a full suite of cytokines and chemokines in both bronchoalveolar lavage and serum.

Treg Summit Oral Presentation details – May 17-19, Boston

Format: Oral presentation
Title: A Revolutionary Approach to Resetting the Immune System for Long-Term Disease Remission
Presenter:  Dr Roly Foulkes, Chief Scientific Officer, Revolo
Presentation Time: Thursday, May 19, 2022, 9:30-10:00 am EDT
Session: Eliciting Durable Responses to Overcome Relapse & Remission
Presentation Highlights:

  • Review of multiple new mechanisms in development directed at proliferating stable and long lasting Tregs to reset the immune system and achieve long term disease remission
  • Discussion of ‘1104, a peptide in phase 2 trials in eosinophilic esophagitis (EoE) and allergic disease
  • Review of proof-of-concept trial of ‘1805 in phase 2 trials in rheumatoid arthritis and non-infectious uveitis

About ‘1104

‘1104 is a first-in-class peptide derived from a natural immune-regulatory protein, mTB Chaperonin 60.1 that is involved in resetting the immune system. Revolo Bio is advancing ‘1104 through two Phase 2 trials: one in patients with eosinophilic esophagitis (EoE) and one in patients with allergen sensitivity, while exploring its potential for other allergic and inflammatory diseases.

About ‘1805

‘1805 is a modified analogue of the endogenous immune-regulatory binding immunoglobulin protein (BiP), a key player in immune function that resets the immune system for long-term disease remission. 1805’s tolerogenic properties have the potential to create effective disease intervention across multiple indications and routes of administration.

About Revolo Biotherapeutics

Revolo Biotherapeutics is developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic disease, without the immune system suppression seen with current therapies. Its two drug candidates, ‘1805 and ‘1104, a protein and a peptide respectively, reset the immune system to prevent the chronic pro-inflammatory immune response that results in autoimmune or allergic disease. ‘1104 is a peptide derived from a natural immune-regulatory protein and is being evaluated in a Phase 2 clinical trial for patients with eosinophilic esophagitis (EoE) and a Phase 2 clinical trial for allergic disease. ‘1805 is a modified analogue of a key protein in immune function that is preparing to enter a second Phase 2 clinical trial for moderate-to-severe rheumatoid arthritis and a Phase 2 clinical trial for non-infectious uveitis. The disease-agnostic mechanism of action of Revolo Biotherapeutic’s assets provides a potential platform for the development of treatments for multiple autoimmune and allergic diseases.

For further information, please visit www.revolobio.com.

Company Contact
Marylyn Rigby, VP Investor Relations & Marketing

Media Contact
Monica Rouco Molina, Ph.D.
LifeSci Communications

Scroll to Top

David Southwell


In addition to his role as Chairman of Revolo, David Southwell serves on the Board of Directors for Rocket Pharmaceuticals and PTC Therapeutics. David is the former CEO of TScan Therapeutics. Before that, he served as President and CEO of Inotek Pharmaceuticals until its merger with Rocket Pharmaceuticals in 2018. David has held other senior leadership roles and Board of Director positions at companies including Human Genome Sciences, Sepracor, Spero Therapeutics, inVentiv Health, and THL Credit.

Kari Brown, M.D.

Executive Vice President, Clinical Development, Operations and Strategy

Kari Brown, a board-certified allergist and immunologist, brings 10 years of experience in clinical treatment deployment, development and strategy to Revolo. In her various roles, Kari has played an integral part in advancing pipelines across allergy and immunology disease indications.

Femi Oluboyede

Vice President, Technical Operations, CMC

Femi Oluboyede has over 20 years of experience within the bio-pharma industry, with a proven track record of achieving strategic corporate objectives. Through his roles, Femi has excelled in fostering alignment across functional teams, including Process Development, Tech-transfers, cGMP Manufacturing in Biologics, Small molecules, Proteins and Synthetic Peptides. He has succeeded in delivering investigational products and providing support across different phases of clinical trials.

Tunde Otulana, M.D.

Non-Executive Director

Tunde is currently the Chief Medical Officer of Veloxis Pharmaceuticals in North Carolina, USA since August 2020. Prior to Veloxis he was Senior Vice President and Chief Medical Officer at Mallinckrodt Pharmaceuticals. His career, which spans about 30 years in industry, government and academia, includes leadership roles at Boehringer Ingelheim Pharmaceutical Inc. and the US Food and Drug Administration (“FDA”). Tunde is a physician trained in Pulmonary and Critical Care Medicine.

Beth Alley

Vice President, Regulatory Affairs

Beth Alley has over 20 years of experience within the biopharmaceutical industry in regulatory affairs, commercial strategy, and medical writing throughout all phases of drug development. Her primary areas of focus have been in development of biologics for treatment of autoimmune, inflammatory, and infectious diseases.

Glen Giovanetti

Non-Executive Director

Glen Giovanetti has more than 35 years of experience in strategy and operational leadership in the life science industry as well as in financial governance, risk and reporting as EY’s Global Biotechnology Sector Leader and Life Sciences Sector Leader. He currently serves on the Board of Directors of Life Science Cares, Teon Therapeutics and XW Pharma.

Marla S. Persky

Non-Executive Director

Marla S. Persky currently serves as the chief executive officer and president of WOMN LLC. She has more than 25 years of international senior business and legal experience in the pharmaceutical industry having held numerous business and legal positions at Boehringer Ingelheim and Baxter International. She currently serves on the Boards of Directors of Xeris Pharmaceuticals, YGEIA Consulting Group, Primary Stages, World Neighbors and A Better Chance in Ridgefield.

Dora Rau

Senior Vice President, Quality

Dora Rau brings 25 years of experience in development and commercial operations for drugs, biologics, devices and combination products to the team. She has held numerous executive-level quality positions, with expertise in building quality systems and in leading teams to attain successful regulatory authority inspection outcomes and product approvals.

Jonathan Gold

Chief Financial Officer

Over the last 25 years, Jonathan Gold has been an institutional venture capitalist, a public fund manager, a founder, an operating executive, and a board member for companies across sectors including life sciences. In those roles, he was active in the development, financing and mergers and acquisitions for numerous public and private companies.

Team Members

Michael Albisser

Non-Executive Director​

Michael is a partner of Metellus, a Zurich and London-based venture capital firm investing in technology and life sciences with ground-breaking potential. Having more than 25 years of experience in the finance area he is responsible for finance, tax, and deal structures. He serves on the board of various venture-backed companies.

Dr. Isaac Cheng, m.d.

Non-Executive Director

Dr. Isaac Cheng is currently an investment professional at Morningside, a venture capital and private equity institution based in Boston USA, and Shanghai China. Dr. Cheng focuses primarily on biopharmaceutical and healthcare investments. He has served on numerous public and private company boards.

Peter Greenleaf

Non-Executive Director

Peter Greenleaf currently serves as the chief executive officer (CEO) and member of the Board of Directors of Aurinia, (NASDAQ: AUPH / TSX: AUP), an autoimmune therapeutics company. He has held several other CEO and chairman roles. He is also currently a member of the Board of Directors of Antares Pharmaceuticals, Inc. (NASDAQ: ATRS) and Chairman of the Board of Directors of Biodelivery Sciences International, Inc. (NASDAQ: BDSI).

Marylyn Rigby

SVP of Marketing and Investor Relations

Marylyn Rigby is an experienced pharmaceutical, biotech, and drug delivery professional. In addition to her expertise in marketing, public and investor relations, she has a successful track record with business development, licensing, public and private equity financing, strategy and other key corporate functions.

Nancy Vinh

SVP of Clinical Operations

Nancy Vinh brings over 20 years of experience in managing early and late phase, international clinical trials for drugs, biologics, cell therapy and combination products across a wide range of therapeutic areas to the team. She has served as head of clinical operations and led registrational and label expansion trials execution.

Team Members

Dr. Clare Burgess

Chief Development Officer

Dr. Clare Burgess has 24 years of experience in clinical drug development as a pharmacologist and has worked across a wide range of therapeutic areas within the pharmaceutical industry. She has held multiple leadership roles and has led multidisciplinary teams across the world.

Jeff Myers, m.d., ph.d

Chief Medical Officer

Jeff Myers, M.D., Ph.D., has 20 years of experience in medical affairs, regulatory and clinical development within the biopharmaceutical industry, with focuses on cardiovascular, pulmonary, oncology, and inflammatory diseases.

Before entering the industry, he practiced as a congenital cardiac surgeon and served as the chief of pediatric cardiac surgery at Massachusetts General Hospital and as Associate Professor of Surgery at Harvard Medical School.

Team Members

Dr. Roly Foulkes

Chief Scientific Officer

A true drug discoverer, Dr. Roly Foulkes has 25 years of experience building and delivering innovative therapeutic portfolios within the immunology and inflammatory disease space. He has a strong record advising small and medium sized immunology biopharma companies in developing competitive therapeutic strategies and bringing new innovative molecules to the clinic.

Team Members

Jones w (woody) Bryan, ph.d.

President & Chief Executive Officer

Jones (Woody) Bryan, Ph.D., brings almost 30 years of experience in the healthcare industry to the team, having led successful business development operations in both private and public pharma and biotech companies.

Team Members

Jonathan Rigby, mba

Group Chief Executive Officer

As employee #1 of Revolo Biotherapeutics in the US, Jonathan Rigby has led the company through substantial and rapid growth. He brings three decades of experience creating value and opportunities for companies in the pharmaceutical, biotech and drug delivery technology industry.

Team Members